Boston Scientific Corporation
BSX
$98.66
$0.490.50%
| Weiss Ratings | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B+ | |||
| Rating Factors | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Good | |||
| Beta / Standard Deviation | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.50 | |||
| Price History | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.82% | |||
| 30-Day Total Return | 8.61% | |||
| 60-Day Total Return | 12.10% | |||
| 90-Day Total Return | 18.78% | |||
| Year to Date Total Return | 10.38% | |||
| 1-Year Total Return | 61.61% | |||
| 2-Year Total Return | 118.81% | |||
| 3-Year Total Return | 123.11% | |||
| 5-Year Total Return | 123.87% | |||
| 52-Week High % Change | -0.48% | |||
| 52-Week Low % Change | 64.85% | |||
| Price | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $99.14 | |||
| 52-Week Low Price | $59.85 | |||
| 52-Week Low Price (Date) | Jan 24, 2024 | |||
| 52-Week High Price (Date) | Jan 17, 2025 | |||
| Valuation | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 145.41B | |||
| Enterprise Value | 154.41B | |||
| Price/Earnings (TTM) | 81.70 | |||
| Earnings Per Share (TTM) | 1.21 | |||
| Earnings Per Share Growth | 47.85% | |||
| Price/Earnings To Growth | 1.71 | |||
| Price/Sales (TTM) | 9.22 | |||
| Price/Book (Q) | 7.02 | |||
| Enterprise Value/Revenue (TTM) | 9.71 | |||
| Price | $98.66 | |||
| Enterprise Value/EBITDA (TTM) | 38.02 | |||
| Enterprise Value/EBIT | 54.62 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.49B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | 0.00% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 508 683 4000 | |||
| Address | 300 Boston Scientific Way Marlborough, MA 01752-1234 | |||
| Website | www.bostonscientific.com | |||
| Country | United States | |||
| Year Founded | 1979 | |||
| Profitability | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 17.76% | |||
| Profit Margin | 11.25% | |||
| Management Effectiveness | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.90% | |||
| Return on Equity | 8.92% | |||
| Income Statement | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 15.91B | |||
| Total Revenue (TTM) | 15.91B | |||
| Revenue Per Share | $10.70 | |||
| Gross Profit (TTM) | 10.94B | |||
| EBITDA (TTM) | 4.06B | |||
| EBIT (TTM) | 2.83B | |||
| Net Income (TTM) | 1.79B | |||
| Net Income Avl. to Common (TTM) | 1.79B | |||
| Total Revenue Growth (Q YOY) | 19.34% | |||
| Earnings Growth (Q YOY) | -7.13% | |||
| EPS Diluted (TTM) | 1.21 | |||
| EPS Diluted Growth (Q YOY) | -6.32% | |||
| Balance Sheet | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.50B | |||
| Cash Per Share (Q) | $1.68 | |||
| Total Current Assets (Q) | 8.76B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 20.96B | |||
| Current Ratio (Q) | 1.482 | |||
| Book Value Per Share (Q) | $14.05 | |||
| Total Assets (Q) | 38.08B | |||
| Total Current Liabilities (Q) | 5.91B | |||
| Total Debt (Q) | 11.26B | |||
| Total Liabilities (Q) | 17.12B | |||
| Total Common Equity (Q) | 20.71B | |||
| Cash Flow | BSX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -3.04B | |||
| Cash from Financing (TTM) | 1.62B | |||
| Net Change in Cash (TTM) | 1.52B | |||
| Levered Free Cash Flow (TTM) | 1.67B | |||
| Cash from Operations (TTM) | 2.94B | |||
